DGS Capital Management LLC Buys 345 Shares of Sanofi (NASDAQ:SNY)

DGS Capital Management LLC grew its holdings in Sanofi (NASDAQ:SNY) by 3.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,194 shares of the company’s stock after purchasing an additional 345 shares during the quarter. DGS Capital Management LLC’s holdings in Sanofi were worth $507,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Clearbridge Investments LLC grew its position in shares of Sanofi by 8.4% in the third quarter. Clearbridge Investments LLC now owns 184,630 shares of the company’s stock valued at $9,904,000 after purchasing an additional 14,362 shares during the last quarter. Dynamic Advisor Solutions LLC acquired a new stake in Sanofi during the fourth quarter worth about $2,104,000. Soros Fund Management LLC bought a new position in Sanofi during the third quarter worth about $11,533,000. Clear Street Markets LLC lifted its stake in Sanofi by 352.8% during the third quarter. Clear Street Markets LLC now owns 130,183 shares of the company’s stock worth $6,983,000 after purchasing an additional 101,430 shares during the period. Finally, BKM Wealth Management LLC bought a new position in Sanofi during the fourth quarter worth about $237,000. 10.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. TheStreet cut shares of Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Finally, Morgan Stanley assumed coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $55.00.

Sanofi Stock Down 0.1 %

NASDAQ:SNY traded down $0.04 on Tuesday, hitting $46.20. 564,562 shares of the company’s stock were exchanged, compared to its average volume of 1,827,493. The firm has a 50-day moving average price of $47.59 and a 200-day moving average price of $48.76. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. Sanofi has a 52 week low of $42.63 and a 52 week high of $57.82. The company has a market cap of $116.87 billion, a P/E ratio of 19.59, a price-to-earnings-growth ratio of 1.72 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). Sanofi had a net margin of 12.56% and a return on equity of 27.47%. The firm had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. As a group, analysts expect that Sanofi will post 4.16 EPS for the current fiscal year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be paid a $1.478 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a yield of 2.98%. This is a positive change from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio is 58.47%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.